Differences in humoral immunogenicity between herpes simplex virus types 1 and 2.
Infection of NMRI mice with increasing doses of six different strains of herpes simplex virus type 1 (HSV-1) induced increasing levels of neutralizing antibodies. In contrast, three strains of HSV-2, irrespective of the dose, induced only marginal antibody responses. Only strain HG 52 (HSV-2) at high doses of infection stimulated antibody formation. The virus content of some organs in 6- to 8-week-old mice appeared to be lower after HSV-2 than after HSV-1 infection. Application of immune-modulating drugs [silica or poly(I) X poly(C) coupled via L-lysine to CM-cellulose] resulted in little augmentation of antibody formation if compared to HSV-1 infection. Secondary infections with HSV-1 or HSV-2 after a primary dose of HSV-1 were followed by a marked booster response. In contrast, a primary infection with HSV-2 suppressed secondary responses of HSV-1 and HSV-2, thus indicating fundamental differences between the antibody-stimulating potency of HSV-1 and HSV-2 strains.
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D001202:Ascitic Fluid / Q000382:microbiology; D002266:Carboxymethylcellulose Sodium / Q000494:pharmacology / Q000031:analogs & derivatives; D003429:Cross Reactions; D003520:Cyclophosphamide / Q000494:pharmacology; D005260:Female; D006561:Herpes Simplex / Q000276:immunology* / Q000382:microbiology; D007156:Immunologic Memory; D007930:Leucine / Q000031:analogs & derivatives / Q000494:pharmacology; D051379:Mice; D008815:Mice, Inbred Strains; D009500:Neutralization Tests; D011070:Poly I-C / Q000494:pharmacology; D011107:Polylysine / Q000494:pharmacology / Q000031:analogs & derivatives; D051381:Rats; D011919:Rats, Inbred Strains; D012703:Serotyping; D012822:Silicon Dioxide / Q000494:pharmacology; D018139:Simplexvirus / Q000145:classification / Q000276:immunology* / Q000302:isolation & purification; D013045:Species Specificity; D013950:Thymus Gland / Q000382:microbiology; D014613:Vaccines, Attenuated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines; D011107:Polylysine; D012822:Silicon Dioxide; C019531:poly ICLC; D003520:Cyclophosphamide; D007930:Leucine; C012211:ubenimex; D002266:Carboxymethylcellulose Sodium; D011070:Poly I-C